Karyopharm Therapeutics Inc
$ 1.96
-7.55%
10 Aug - close price
- Market Cap 48,045,400 USD
- Current Price $ 1.96
- High / Low $ 2.18 / 1.92
- Stock P/E N/A
- Book Value -11.78
- EPS -16.40
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.41 %
- ROE -8.91 %
- 52 Week High 10.99
- 52 Week Low 1.80
About
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
Analyst Target Price
$6.40
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-10 | 2026-05-14 | 2026-02-12 | 2025-11-03 | 2025-08-11 | 2025-05-12 | 2025-02-19 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-02-29 | 2023-11-02 |
| Reported EPS | None | -1.24 | -2.23 | -3.82 | -4.07 | -2.77 | -3.6 | -3.9 | -4.34 | -4.8 | -0.36 | -4.5 |
| Estimated EPS | -1.53 | -1.44 | -2 | -3.25 | -3.91 | -3.09 | -4.03 | -3.92 | -4.47 | -4.94 | -0.31 | -4.29 |
| Surprise | 0 | 0.2 | -0.23 | -0.57 | -0.16 | 0.32 | 0.43 | 0.02 | 0.13 | 0.14 | -0.05 | -0.21 |
| Surprise Percentage | None% | 13.8889% | -11.5% | -17.5385% | -4.0921% | 10.356% | 10.67% | 0.5102% | 2.9083% | 2.834% | -16.129% | -4.8951% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.53 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KPTI
2026-08-10 11:11:31
Karyopharm Therapeutics (Nasdaq: KPTI) announced it will report its second-quarter 2026 financial results on August 13, 2026, including a conference call and live audio webcast with accompanying slides at 8:00 a.m. ET. The company will discuss results and provide updates, with an archived replay available afterward. This earnings report follows recent insider selling and high short-interest signals for KPTI.
2026-08-10 11:11:30
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss the results and provide other company updates. Karyopharm is a commercial-stage pharmaceutical company focused on novel cancer therapies, with its lead product XPOVIO® (selinexor) approved for multiple myeloma.
2026-08-07 16:41:53
Karyopharm Therapeutics Inc. is projected to report a loss of $1.28 per share, according to an earnings preview. This information comes from Refinitiv, as reported by Reuters. The full article is available to TradingView subscribers.
2026-08-06 23:02:00
Pomerantz LLP is investigating potential securities fraud claims against Karyopharm Therapeutics Inc. (NASDAQ: KPTI) on behalf of investors. This investigation follows a disclosure by Karyopharm on July 17, 2026, revealing a retention program that awarded top executives significant cash bonuses. Following this news, Karyopharm's stock price dropped by 21.45% on July 20, 2026.
2026-08-05 15:41:36
Karyopharm Therapeutics is preparing an sNDA submission in August 2026 for accelerated approval of its selinexor-ruxolitinib combination therapy for myelofibrosis, based on positive Phase 3 SENTRY trial data showing significant spleen volume reduction. The FDA has accepted SVR35 as a surrogate endpoint for accelerated approval in this rare blood cancer, which affects thousands of patients in the US and EU. Despite recent analyst target reductions due to a separate trial miss, institutional ownership remains high, signaling confidence in Karyopharm's myelofibrosis program.
2026-08-05 04:41:34
This article discusses analyst ratings for two healthcare companies: Teladoc (TDOC) and Karyopharm Therapeutics (KPTI). Teladoc received a "Hold" rating from TD Cowen and Citi, with a consensus price target indicating a modest upside. Karyopharm Therapeutics, on the other hand, received "Buy" ratings from RBC Capital and Piper Sandler, with a much higher implied upside from its consensus price target.
